150 related articles for article (PubMed ID: 36271070)
21. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
22. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
[TBL] [Abstract][Full Text] [Related]
23. Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer.
Shiraishi T; Sasaki T; Ikeda K; Tsukada Y; Nishizawa Y; Ito M
BMC Cancer; 2019 Dec; 19(1):1222. PubMed ID: 31842797
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin-based adjuvant chemotherapy rather than fluorouracil-based chemotherapy in rectal cancer is more efficient to decrease distant metastasis and increase survival after preoperative chemoradiotherapy and surgery: a meta-analysis.
Song JH; Lee JH; Kim SH; Um JW;
Int J Colorectal Dis; 2022 Mar; 37(3):649-656. PubMed ID: 35050402
[TBL] [Abstract][Full Text] [Related]
26. [Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer].
Sun R; Cong L; Qiu HZ; Lin GL; Wu B; Niu BZ; Sun XY; Zhou JL; Xu L; Lu JY; Xiao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):522-530. PubMed ID: 35754217
[No Abstract] [Full Text] [Related]
27. The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional mismatch Repair Proficient Rectal Cancer.
Bhudia J; Glynne-Jones R
Curr Treat Options Oncol; 2022 Apr; 23(4):453-473. PubMed ID: 35312962
[TBL] [Abstract][Full Text] [Related]
28. Nonmetastatic ypt0 rectal cancer after neoadjuvant treatment and total mesorectal excision: Lessons from a retrospective multicentric cohort of 383 patients.
Collard MK; Rullier E; Panis Y; Manceau G; Benoist S; Tuech JJ; Alves A; Laforest A; Mege D; Cazelles A; Beyer-Berjot L; Christou N; Cotte E; Lakkis Z; O'Connell L; Parc Y; Piessen G; Lefevre JH;
Surgery; 2022 May; 171(5):1193-1199. PubMed ID: 35078629
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
[TBL] [Abstract][Full Text] [Related]
30. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Lymph Node Ratio in Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision.
Zuo ZG; Zhang XF; Wang H; Liu QZ; Ye XZ; Xu C; Wu XB; Cai JH; Zhou ZH; Li JL; Song HY; Luo ZQ; Li P; Ni SC; Jiang L
Medicine (Baltimore); 2016 Mar; 95(9):e2988. PubMed ID: 26945418
[TBL] [Abstract][Full Text] [Related]
32. Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
Koo T; Song C; Kim JS; Kim K; Chie EK; Kang SB; Lee KW; Kim JH; Jeong SY; Kim TY
PLoS One; 2015; 10(9):e0138728. PubMed ID: 26381522
[TBL] [Abstract][Full Text] [Related]
33. Total neoadjuvant treatment for MRI-stratified high-risk rectal cancer: a single-center, single-arm, prospective Phase II trial (PKUCH-R02).
Chen PJ; Wang L; Sun TT; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Cai Y; Li YH; Zhang XY; Sun YS; Li ZW; Wang WH; Wu AW
Gastroenterol Rep (Oxf); 2023; 11():goad017. PubMed ID: 37082450
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
D'Alimonte L; Bao QR; Spolverato G; Capelli G; Del Bianco P; Albertoni L; De Paoli A; Guerrieri M; Mantello G; Gambacorta MA; Canzonieri V; Valentini V; Coco C; Pucciarelli S
Ann Surg Oncol; 2021 May; 28(5):2801-2808. PubMed ID: 33125570
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.
Park IJ; You YN; Skibber JM; Rodriguez-Bigas MA; Feig B; Nguyen S; Hu CY; Chang GJ
Dis Colon Rectum; 2013 Feb; 56(2):135-41. PubMed ID: 23303140
[TBL] [Abstract][Full Text] [Related]
36. Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer.
Lee SJ; Kang BW; Chae YS; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
Ann Surg Oncol; 2016 Mar; 23(3):894-9. PubMed ID: 26714957
[TBL] [Abstract][Full Text] [Related]
37. The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial.
Hu YH; Wei JW; Chang H; Xiao WW; Lin JZ; Cai MY; Cai PQ; Kong LH; Chen G; Pan ZZ; Zeng ZF; Ding PR; Gao YH
Cancer Manag Res; 2018; 10():4363-4369. PubMed ID: 30349369
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].
Zhang YQ; Sun KG; Lu JY; Ma J; Yao N; Qin ZH; Yao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):531-538. PubMed ID: 35754218
[No Abstract] [Full Text] [Related]
39. Contemporary management of locally advanced rectal cancer: Resolving issues, controversies and shifting paradigms.
Nacion AJD; Park YY; Kim NK
Chin J Cancer Res; 2018 Feb; 30(1):131-146. PubMed ID: 29545727
[TBL] [Abstract][Full Text] [Related]
40. Consolidation chemotherapy may improve pathological complete response for locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a retrospective study.
Cui J; Dou X; Sun Y; Yue J
PeerJ; 2020; 8():e9513. PubMed ID: 32704453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
